Biomarkers for Immune Checkpoint Inhibitor Response in NSCLC: Current Developments and Applicability

Autor(es)

Tostes, Katiane ; Siqueira, Alexia Polo ; Reis, Rui Manuel ; Leal, Leticia Ferro ; Arantes, Lidia Maria Rebolho Batista

• Tipo de documento: Artigo Científico
• Fonte: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES; v. 24, n. 15, p. 18-pg., 2023-08-01.

Resumo

Lung cancer has the highest mortality rate among all cancer types, resulting in over 1.8 million deaths annually. Immunotherapy utilizing immune checkpoint inhibitors (ICIs) has revolutionized the treatment of non-small cell lung cancer (NSCLC). ICIs, predominantly monoclonal antibodies, modulate co-stimulatory and co-inhibitory signals crucial for maintaining immune tolerance. Despite significant therapeutic advancements in NSCLC, patients still face challenges such as disease progression, recurrence, and high mortality rates. Therefore, there is a need for predictive biomarkers that can guide lung cancer treatment strategies. Currently, programmed death-ligand 1 (PD-L1) expression is the only established biomarker for predicting ICI response. However, its accuracy and robustness are not consistently reliable. This review provides an overview of potential biomarkers currently under development or in the validation stage that hold promise in improving the classification of responders and non-responders to ICI therapy in the near future. (AU)

• Processo FAPESP: 21/08352-0 - Inibidores do checkpoint imunológico: biomarcadores para predição de resposta em pacientes com Câncer de Pulmão de células não pequenas
• Beneficiário: Katiane Tostes
• Modalidade de apoio: Bolsas no Brasil - Doutorado Direto
• Processo FAPESP: 21/04100-6 - Inibidores de checkpoint imunológico: imunofenotipagem e desfecho clínico para predição de resposta no Hospital de Câncer de Barretos
• Beneficiário: Lidia Maria Rebolho Batista Arantes
• Modalidade de apoio: Bolsas no Brasil - Jovens Pesquisadores
• Processo FAPESP: 19/07111-9 - Inibidores de checkpoint imunológico: imunofenotipagem e desfecho clínico para predição de resposta no Hospital de Câncer de Barretos
• Beneficiário: Lidia Maria Rebolho Batista Arantes
• Modalidade de apoio: Auxílio à Pesquisa - Jovens Pesquisadores